MedTrace Logo

Pharmacogenetic-Directed Treatment for Major Depression

NCT01261364 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-12-03

No results posted yet for this study

Summary

Determine if antidepressant treatment guided by pharmacogenetic algorithm and interpretive report improves outcomes when compared with standard treatment without the availability of genetic information.

Conditions

Interventions

BEHAVIORAL

GeneSightRx

Multi-genetic pharmacogenomic panel

BEHAVIORAL

Treatment as usual

Treatment as usual

Sponsors & Collaborators

  • Pine Rest Christian Mental Health Services

    collaborator OTHER

  • Assurex Health Inc.

    lead INDUSTRY

Principal Investigators

  • Kevin Furmaga, PharmD · Pine Rest Mental Health Service

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-01-31
Completion
2011-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261364 on ClinicalTrials.gov